Table 1.
Baseline patient characteristics
| Patient characteristics (n = 41) | |
|---|---|
| Age, years | 53.3 (11.3) |
| Female gender, N (%) | 24 (58.5) |
| Disease duration, years | 10 (9) |
| Smoking, N (%) | |
| Current smoker | 5 (12.2) |
| Ex-smoker | 13 (31.7) |
| Never smoker | 23 (56.1) |
| Remission duration, months | 16.7 (14.4) |
| DAS-28 ESR, units | 1.62 (0.68) |
| ESR, mm/h | 11.5 (9.5) |
| CRP, mg/dL | 0.26 (0.51) |
| Positive RF, N (%) | 26 (63.4) |
| Positive ACPA, N (%) | 28 (68.3) |
| Methotrexate use, N (%) | 27 (65.9) |
| Other csDMARD use, N (%) | 2 (4.9) |
| Biological DMARD use, N (%) | |
| Adalimumab | 14 (34.1) |
| Tocilizumab | 10 (24.4) |
| Etanercept | 9 (22.0) |
| Certolizumab pegol | 6 (14.6) |
| Golimumab | 2 (4.9) |
| Patients with flare, N (%) | 20 (48.8) |
Values are means (SD) if not stated otherwise
ACPA anti-citrullinated peptide antibodies, CRP C-reactive protein, DAS-28 Disease Activity Score 28 joints, DMARD disease-modifying anti-rheumatic drugs, cs conventional synthetic, ESR erythrocyte sedimentation rate